HER2-POZİTİF LOKAL İLERİ MEME KANSERİNDE NEOADJUVAN TRASTUZUMAB SIRALAMASININ PATOLOJİK TAM YANIT ÜZERİNE ETKİSİ The effect of neoadjuvant trastuzumab treatment sequence on pathologic complete response in HER2-positive locally advanced breast cancer
Amaç: Trastuzumabın meme kanserinde neoadjuvan tedaviye eklenmesiyle patolojik tam yanıt (PTY) oranını
arttırdığı bilinmektedir. Ancak trastuzumabın kullanım sırasıyla ilgili kısıtlı veri bulunmaktadır. HER2 pozitif
lokal ileri meme kanserinde neoadjuvan trastuzumab uygulama sırasının PTY üzerine etkisi olup olmadığını
incelemeyi amaçladık.
Gereç ve Yöntemler: 2010-2018 yılları arasında HER2 pozitif evre 2 ve 3 meme kanseri nedeniyle neoadjuvan
trastuzumab kullanan hastaların verileri retrospektif incelenmiş olup antrasiklin bazlı tedavi sonrası
trastuzumab alan 30 hasta ve tam tersi sıralama ile tedavi alan 16 hasta çalışmaya alındı.
Bulgular: Çalışmaya toplam 46 hasta alınmış olup ortanca takip süresi 31 aydı (aralık; 7–98). Hastaların ortanca
yaşı 51 yıldı (19–72). Tüm hastaların %52’si postmenopozal, %67'si hormon reseptör pozitifti. Tüm
hastalarda klinik nod pozitifliği olup %54'ü cN1 idi. Hastalar trastuzumab sıralamasına göre grupla ayrıldı.
Bazal özellikler açısından gruplar arasında fark yoktu. PTY oranı trastuzumab ile tedaviye başlayanlarda %63
olup diğer grupta %37 idi (p=0.1). Üç yıllık kümülatif hastalıksız sağ kalım oranları ise sırasıyla %100 ve %80
idi (p=0.2). Tek değişkenli analizde evre 2 ve Vücut kitle indeksi (VKİ)
Physical Therapy and Balneotherapy in Elderly Patients with Neck, Low Back and Knee Pain, Retrospective Study
Objective: The aim of this study was to investigate the contribution of balneotherapy to physical therapy in elderly people with neck, low back and knee pain. Materials and methods: In this retrospective study, the records of patients who received physical therapy or physical therapy + balneotherapy between 2013 and 2018 were examined. The data of 482 patients withthe exact evaluation parameters were analyzed among 704 elderly patients. Results: Only 196 patients had physical therapy (group 1). 286 patients underwent both physical therapyand balneotherapy (group 2). The treatment was applied to 173 patients from the neck, 338 patients from the low back and 287 patients from the knee. Some patients received treatment from two regions. In the general evaluation, the Pain Visual Analog Scale (VAS) results in 482 patients and the Health Assessment Questionnaire (HAQ) results in 276 patients, VAS results in 173 patients and HAQ results in 120 patients who received treatment from the neck, VAS results in 338 patients and HAQ results in 238 patients who received treatment from the low back and VAS results in 287 patients and HAQ results in 177 patients who received treatment from the knee results were examined. A statistically significant improvement was found in all outcome measures evaluated after treatment (p<0.001). In Group 2, recovery rates were statistically higher than group 1 (in all parameters p<0.001). Conclusion: At the end of this study, physical therapy combined with balneotherapy in elderly patients suffering from neck, low back and knee pain were found to be more effective on pain and quality of life than on physical therapy alone. Balneotherapy applied to the whole body may increase the effectiveness of physical therapy
___
- 1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4(11):1553-68.
2. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188-94.
3. Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27-39.
4. Buzdar AU. Preoperative chemotherapy treatment of breast cancer--a review. Cancer. 2007;110(11):2394-407.
5. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G et al. Preoperative ther apy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26(5):814-19.
6. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(13):1317-25.
7. Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer. 2010;116(12):2856-67.
8. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US. Cancer Invest. 2010;28(9):963-8.
9. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.